Emerging treatment options for management of malignant ascites in patients with ovarian cancer

International Journal of Women's Health

Volumn 4, Issue 1, 2012, Pages 395-404

  Eskander, Ramez N ^a   Tewari, Krishnansu S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; Ascites; Epithelial ovarian cancer

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CATUMAXOMAB; PACLITAXEL; PLACEBO; VASCULOTROPIN;

ABDOMINAL PAIN; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; CHILL; DIARRHEA; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPHONIA; FATIGUE; FEVER; HEADACHE; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOTENSION; ILEUS; INTERMETHOD COMPARISON; INTESTINE PERFORATION; LEUKOCYTOSIS; LYMPHOCYTOPENIA; MALIGNANT ASCITES; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; OVARY CANCER; PARACENTESIS; PROTEINURIA; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SMALL INTESTINE OBSTRUCTION; STOMACH HEMORRHAGE; TACHYCARDIA; TREATMENT OUTCOME; TUMOR VASCULARIZATION; VOMITING; WEIGHT REDUCTION;

EID: 84865053836     PISSN: None     EISSN: 11791411     Source Type: Journal    
DOI: 10.2147/IJWH.S29467     Document Type: Review

References (61)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.
2. Bookman M. Trials with impact on clinical management: first line. Int J Gynecol Cancer. 2009;19 Suppl 2:S55-S62.
3. Ozols R, Bundy B, Greer B, etal. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21(17):3194-3200.
4. Monk B, Choi D, Pugmire G, Burger R. Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. Gynecol Oncol. 2005;96(3):902-905.
5. Cannistra S. Evaluating new regimens in recurrent ovarian cancer: how much evidence is good enough? J Clin Oncol. 2010;28(19): 3101-3103.
6. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, etal. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010;28(20):3323-3329.
7. Cannistra S. Is there a "best" choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer? J Clin Oncol. 2002;20(5):1158-1160.
8. Eskander RN, Randall LM. Bevacizumab in the treatment of ovarian cancer. Biologics. 2011;5:1-5.
9. Malayev Y, Levene R, Gonzalez F. Palliative chemotherapy for malignant ascites secondary to ovarian cancer. Am J Hosp Palliat Care. February 23, 2012. [Epub ahead of print.]
10. Loggie BW, Perini M, Fleming RA, Russell GB, Geisinger K. Treatment and prevention of malignant ascites associated with disseminated intraperitoneal malignancies by aggressive combined-modality therapy. Am Surg. 1997;63(2):137-143.
11. Barni S, Cabiddu M, Ghilardi M, Petrelli F. A novel perspective for an orphan problem: old and new drugs for the medical management of malignant ascites. Crit Rev Oncol Hematol. 2011;79(2):144-153.
12. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
13. Becker G, Blum HE. VEGF trap for the treatment of malignant ascites. Lancet Oncol. 2012;13(2):115-116.
14. Garrison RN, Galloway RH, Heuser LS. Mechanisms of malignant ascites production. J Surg Res. 1987;42(2):126-132.
15. Adam RA, Adam YG. Malignant ascites: past, present, and future. J Am Coll Surg. 2004;198(6):999-1011.
16. Qazi R, Savlov ED. Peritoneovenous shunt for palliation of malignant ascites. Cancer. 1982;49(3):600-602.
17. Ariel IM, Oropeza R, Pack GT. Intracavitary administration of radioactive isotopes in the control of effusions due to cancer. Results in 267 patients. Cancer. 1966;19(8):1096-1102.
18. Runyon BA. Care of patients with ascites. N Engl J Med. 1994;330(5):337-342.
19. Gotlieb WH, Feldman B, Feldman-Moran O, etal. Intraperitoneal pressures and clinical parameters of total paracentesis for palliation of symptomatic ascites in ovarian cancer. Gynecol Oncol. 1998;71(3):381-385.
20. Becker G, Galandi D, Blum HE. Malignant ascites: systematic review and guideline for treatment. Eur J Cancer. 2006;42(5):589-597.
21. Keen A, Fitzgerald D, Bryant A, Dickinson HO. Management of drainage for malignant ascites in gynaecological cancer. Cochrane Database Syst Rev. 2010;1:CD007794.
22. Stark RH, Sauter KE. Surgical treatment of adenocarcinoma of the stomach in a community hospital. Surg Gynecol Obstet. 1985;160(2):153-156.
23. Ostrowski MJ, Halsall GM. Intracavitary bleomycin in the management of malignant effusions: a multicenter study. Cancer Treat Rep. 1982;66(11):1903-1907.
24. Maat B, Oosterlee J, Spaas JA, White H, Lammes FB. Dissemination of tumour cells via LeVeen shunt. Lancet. 1979;1(8123):988.
25. Paladine W, Cunningham TJ, Sponzo R, Donavan M, Olson K, Horton J. Intracavitary bleomycin in the management of malignant effusions. Cancer. 1976;38(5):1903-1908.
26. Burger RA. Antiangiogenic agents should be integrated into the standard treatment for patients with ovarian cancer. Ann Oncol. 2011;22 Suppl 8:viii65-viii68.
27. Burger RA. Overview of anti-angiogenic agents in development for ovarian cancer. Gynecol Oncol. 2011;121(1):230-238.
28. Ferrara N. VEGF as a therapeutic target in cancer. Oncology. 2005;69 Suppl 3:11-16.
29. Monk BJ, Han E, Josephs-Cowan CA, Pugmire G, Burger RA. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol Oncol. 2006;102(2):140-144.
30. Paley PJ, Staskus KA, Gebhard K, etal. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer. 1997;80(1):98-106.
31. Senger DR, Van de Water L, Brown LF, etal. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev. 1993;12(3-4):303-324.
32. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med (Berl). 1999;77(7):527-543.
33. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int. 1999;56(3):794-814.
34. Ferrara N. Vascular endothelial growth factor: molecular and biological aspects. Curr Top Microbiol Immunol. 1999;237:1-30.
35. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438(7070):967-974.
36. Shalaby F, Rossant J, Yamaguchi TP, etal. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 1995;376(6535):62-66.
37. Zebrowski BK, Liu W, Ramirez K, Akagi Y, Mills GB, Ellis LM. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol. 1999;6(4):373-378.
38. Byrne AT, Ross L, Holash J, etal. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res. 2003;9(15):5721-5728.
39. Xu L, Yoneda J, Herrera C, Wood J, Killion JJ, Fidler IJ. Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int J Oncol. 2000;16(3):445-454.
40. Stoelcker B, Echtenacher B, Weich HA, Sztajer H, Hicklin DJ, Mannel DN. VEGF/Flk-1interaction, a requirement for malignant ascites recurrence. J Interferon Cytokine Res. 2000;20(5):511-517.
41. Kobold S, Hegewisch-Becker S, Oechsle K, Jordan K, Bokemeyer C, Atanackovic D. Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites? Oncologist. 2009;14(12):1242-1251.
42. Numnum TM, Rocconi RP, Whitworth J, Barnes MN. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol. 2006;102(3):425-428.
43. Hamilton CA, Maxwell GL, Chernofsky MR, Bernstein SA, Farley JH, Rose GS. Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol Oncol. 2008;111(3):530-532.
44. Kesterson JP, Mhawech-Fauceglia P, Lele S. The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report. Gynecol Oncol. 2008;111(3):527-529.
45. Stewart MW, Grippon S, Kirkpatrick P. Aflibercept. Nat Rev Drug Discov. 2012;11(4):269-270.
46. Stewart MW. Aflibercept (VEGF trap-eye): the newest anti-VEGF drug. Br J Ophthalmol. March 23, 2012. [Epub ahead of print.]
47. Kim ES, Serur A, Huang J, etal. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci U S A. 2002;99(17):11399-11404.
48. Huang J, Frischer JS, Serur A, etal. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci U S A. 2003;100(13):7785-7790.
49. Hu L, Hofmann J, Holash J, Yancopoulos GD, Sood AK, Jaffe RB. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res. 2005;11(19 Pt 1):6966-6971.
50. Lockhart AC, Rothenberg ML, Dupont J, etal. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol. 2010;28(2):207-214.
51. Gaya A, Tse V. A preclinical and clinical review of aflibercept for the management of cancer. Cancer Treat Rev. January 19, 2012. [Epub ahead of print.]
52. Teng LS, Jin KT, He KF, Zhang J, Wang HH, Cao J. Clinical applications of VEGF-trap (aflibercept) in cancer treatment. J Chin Med Assoc. 2010;73(9):449-456.
53. Colombo N, Mangili G, Mammoliti S, etal. A Phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites. Gynecol Oncol. 2012;125(1):42-47.
54. Gotlieb WH, Amant F, Advani S, etal. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a Phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol. 2012;13(2):154-162.
55. Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood. 2001;98(8):2526-2534.
56. Zeidler R, Mysliwietz J, Csanady M, etal. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer. 2000;83(2):261-266.
57. Heiss MM, Murawa P, Koralewski P, etal. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized Phase II/III trial. Int J Cancer. 2010;127(9):2209-2221.
58. Heiss MM, Strohlein MA, Jager M, etal. Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer. 2005;117(3):435-443.
59. Burges A, Wimberger P, Kumper C, etal. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study. Clin Cancer Res. 2007;13(13):3899-3905.
60. Pietzner K, Jager M, Schoberth A, etal. First patient treated with a re-challenge of catumaxomab in recurrent malignant ascites: a case report. Med Oncol. 2012;29(2):1391-1396.
61. K. El-Shami AE, Y. El-Kerm. Open-label safety and efficacy pilot trial of intraperitoneal bevacizumab as palliative treatment in refractory malignant ascites. J Clin Oncol. 2007;25(No. 18S (June 20 Supplement):9043.